Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Methylene Blue in High-Dose Vasopressor-Dependent Septic Shock
ChiCTR2500112352Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in septic shock comparing Methylene Blue Group with Control Group (Placebo 5% glucose) (2 arms). Primary endpoint: 28-day all-cause mortality. Started Nov 2025; status: recruiting.
02
Drugs
methylene blue
03
Conditions
septic shock
Beyond the preview
Go deeper on ChiCTR2500112352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112352.